Kraj: Australia
Język: angielski
Źródło: Department of Health (Therapeutic Goods Administration)
entecavir monohydrate, Quantity: 0.532 mg
Cipla Australia Pty Ltd
entecavir monohydrate
Tablet, film coated
Excipient Ingredients: hyprolose; magnesium stearate; crospovidone; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 6000
Oral
30, 10
(S4) Prescription Only Medicine
CIPLA ENTECAVIR is indicated for the treatment of chronic hepatitis B virus infection in adults 16 years or older with evidence of active liver inflammation.,This indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment na?ve and lamivudine-resistant adult patients with HBeAg-positive or HBeAg-negative chronic HBV infection with compensated liver disease.
Visual Identification: white to off-white, triangular shaped, biconvex, film coated tablet, debossed with 'E' on one side and plain on the other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Licence status A
2016-12-19